Humanized IL-1α Binding Proteins for Inflammatory Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IL-1α-mediated diseases are inadequate, and there is a need for improved antibodies that can bind and neutralize IL-1α with high affinity to effectively inhibit its inflammatory effects.
Innovation Solution
Development of a novel family of binding proteins, including CDR-grafted, humanized antibodies, and their fragments, which specifically bind to IL-1α with high affinity and neutralize its activity, providing a therapeutic means to treat inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for IL-1α-mediated diseases are used, then treatment is provided, but the treatment is inadequate and does not effectively inhibit inflammatory effects
Solution Approach 1:
The patent develops antibodies with optimized binding parameters (affinity, specificity) to IL-1α. By changing the molecular parameters of the therapeutic agent (antibody structure, binding constant), the treatment effectiveness is improved while maintaining ability to neutralize inflammatory effects
Solution Approach 2:
The patent creates humanized and fully human antibodies that replicate and improve upon natural immune system components. These engineered antibodies copy the neutralization function of natural antibodies while enhancing binding affinity and therapeutic effectiveness against IL-1α
2Reliability
If high affinity binding proteins are developed, then neutralization of IL-1α is improved, but the complexity of the therapeutic agent increases
Solution Approach 1:
The patent extracts and optimizes specific regions of antibodies (CDR regions) that are responsible for binding affinity. By focusing on these critical binding regions and grafting them onto simplified frameworks, high affinity is achieved without requiring complete complex antibody structures
Solution Approach 2:
The patent divides the antibody into functional segments (variable regions, constant regions, CDRs, frameworks) that can be independently optimized. This segmentation allows creation of humanized antibodies that combine high-affinity binding regions with simplified human frameworks, reducing overall complexity while maintaining high affinity
Data Source
AI summary
The present invention encompasses IL-1α binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Antibodies of the invention have high affinity for IL-1α and neutralize IL-1α activity. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting IL-1α and for inhibiting IL-1α activity, e.g., in a human subject suffering from a disorder in which IL-1α activity is detrimental.